UK markets closed

LAVA Therapeutics N.V. (LVTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.6400-0.1000 (-3.63%)
As of 11:32AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 72.03M
Enterprise value -17.23M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)10.82
Price/book (mrq)1.41
Enterprise value/revenue -2.54
Enterprise value/EBITDA 0.43

Trading information

Stock price history

Beta (5Y monthly) 0.63
52-week change 376.77%
S&P500 52-week change 322.64%
52-week high 36.4700
52-week low 31.1310
50-day moving average 32.7632
200-day moving average 31.9044

Share statistics

Avg vol (3-month) 31.16M
Avg vol (10-day) 3152.72k
Shares outstanding 526.29M
Implied shares outstanding 628.6M
Float 812.07M
% held by insiders 128.72%
% held by institutions 133.16%
Shares short (15 Apr 2024) 4193.84k
Short ratio (15 Apr 2024) 40.5
Short % of float (15 Apr 2024) 41.21%
Short % of shares outstanding (15 Apr 2024) 40.74%
Shares short (prior month 15 Mar 2024) 4322.14k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,541.64%

Management effectiveness

Return on assets (ttm)-22.06%
Return on equity (ttm)-61.18%

Income statement

Revenue (ttm)6.77M
Revenue per share (ttm)0.25
Quarterly revenue growth (yoy)-86.60%
Gross profit (ttm)N/A
EBITDA -42.64M
Net income avi to common (ttm)-41.97M
Diluted EPS (ttm)-1.5700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)95.57M
Total cash per share (mrq)3.63
Total debt (mrq)6.31M
Total debt/equity (mrq)12.34%
Current ratio (mrq)6.62
Book value per share (mrq)1.95

Cash flow statement

Operating cash flow (ttm)-38.97M
Levered free cash flow (ttm)-24.82M